Possible involvement of caveolin in attenuation of cardioprotective effect of ischemic preconditioning in diabetic rat heart

BMC Cardiovascular Disorders

Volumn 11, Issue , 2011, Pages

  Ajmani, Preeti ^a   Yadav, Harlokesh N ^a   Singh, Manjeet ^a   Sharma, Pyare L ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXY DEACONATE; CAVEOLIN; CREATINE KINASE MB; DAIDZEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LACTATE DEHYDROGENASE; NITRIC OXIDE; NITRITE; POTASSIUM CHANNEL BLOCKING AGENT; SODIUM NITRITE; TRIPHENYLTETRAZOLIUM; UNCLASSIFIED DRUG; CAV PROTEIN, RAT; CAVEOLIN 1; NOS3 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; ENZYME ACTIVITY; ENZYME RELEASE; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISCHEMIC PRECONDITIONING; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION; STAINING; STREPTOZOCIN DIABETES; UPREGULATION; ANIMAL; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG ANTAGONISM; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; FEMALE; HEART INFARCTION PREVENTION; HEART MUSCLE; MALE; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; SECRETION; WISTAR RAT;

ANIMALS; CAVEOLIN 1; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, WISTAR;

EID: 79960200894     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-11-43     Document Type: Article

References (69)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997, 349(9064):1498-1504. 10.1016/S0140-6736(96)07492-2, 9167458.
2. Vandormael M, Grines CL, George BS, Sanz ML, Wall T, O'Brien M, Schwaiger M, Aguirre FV, et al. The thrombolysis and angioplasty in myocardial infarction. A randomized trial of late reperfusion therapy for acute myocardial infarction. Circulation 1992, 85(6):2090-2099.
3. Baxter GF, Ebrahim Z. Role of bradykinin in preconditioning and protection of the ischaemic myocardium. Br J Pharmacol 2002, 135(4):843-854. 10.1038/sj.bjp.0704548, 1573212, 11861312.
4. Piper HM, Abdullah Y, Schafer XXX. The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res 2004, 61(3):365-371. 10.1016/j.cardiores.2003.12.012, 14962469.
5. Lindell SL, Klahn SL, Piazza TM, Mangino MJ, Torrealba JR, Southard JH, Carey HV. Natural resistance to liver cold ischemia-reperfusion injury associated with the hibernation phenotype. Am J Physiol Gastrointest Liver Physiol 2005, 288(3):G473-G480.
6. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of "Modified Reperfusion" protects the myocardium by activating the Phosphatidylinositol 3-Kinase-Akt Pathway. Circ Res 2004, 95:230-232. 10.1161/01.RES.0000138303.76488.fe, 15242972.
7. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 2005, 54(8):2360-2364. 10.2337/diabetes.54.8.2360, 16046302.
8. Mejía-Vilet JM, Ramírez V, Cruz C, Uribe N, Gamba G, Bobadilla NA. Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am J Physiol Renal Physiol 2007, 293:78-86.
9. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74(5):1124-1136. 10.1161/01.CIR.74.5.1124, 3769170.
10. Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter GF, Holmes AB, McCormick F, Hawkins PT. Dual Role of Phosphatidylinositol-3,4,5 trisphosphate in the activation of Protein Kinase B. Science 1997, 277(5325):567-570. 10.1126/science.277.5325.567, 9228007.
11. Garg K, Yadav HN, Singh M, Sharma PL. Mechanism of Cardioprotective Effect of Erythropoietin-induced Preconditioning in Rat Heart. Indian J Pharmacol 2010, 42(4):219-223. 10.4103/0253-7613.68421, 2941611, 20927246.
12. Ferdinandy P, Schulz R, Baxter GF. Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning and Postconditioning. Pharmacol Rev 2007, 59(4):418-458. 10.1124/pr.107.06002, 18048761.
13. Prendes MGM, Gonzalez M, Savino EA, Varela A. Role of endogenous nitric oxide in classic preconditioning in rat hearts. Regulatory Peptides 2007, 139(1-3):141-145. 10.1016/j.regpep.2006.10.015, 17188373.
14. Ferdinandy P, Szilvassy Z, Baxter GF. Adaptation to myocardial stress in disease states: is preconditioning a healthy heart phenomenon?. Trends Pharmacol Sci 1998, 19:223-229. 10.1016/S0165-6147(98)01212-7, 9666713.
15. Ferdinandy P. Myocardial ischaemia/reperfusion injury and preconditioning: Effects of hypercholesterolaemia/hyperlipidaemia. Br J Pharmacol 2003, 138(2):283-285. 10.1038/sj.bjp.0705097, 1573675, 12540517.
16. Abete P, Ferrara N, Cioppa A, Ferrara P, Bianco S, Calabrese C, Cacciatore F, Longobardi G, Rengo F. Preconditioning does not prevent postischemic dysfunction in aging heart. J Am Coll Cardiol 1996, 27(7):1777-1786. 10.1016/0735-1097(96)00070-8, 8636568.
17. o- Opioid Receptor Stimulation on Ca2+ Homeostasis in Rat Ventricular Myocytes Subjected to Ischemic Insults. J Pharmacol Exp Ther 2004, 310:606-613. 10.1124/jpet.104.067926, 15051801.
18. Snoeckx LH, Van Der Vuesse GJ, Coumans WA, Willemsen PH, Reneman RS. Differences in ischaemia tolerance between hypertrophied hearts of adult and aged spontaneously hypertensive rats. Cardiovasc Res 1996, 27(5):874-881.
19. Snoeckx LH, Van D, Vusse GJ, Coumans WA, Willemsen PHM, Van D, Nagel T, Reneman RS. Myocardial function in normal and spontaneously hypertensive rats during reperfusion after a period of global ischemia. Cardiovasc Res 1986, 20(1):67-75. 10.1093/cvr/20.1.67, 2939955.
20. Sasaki H, Ogawa K, Shimizu M, Mori C, Takatsuka H, Okazaki F, Kawai M, Taniguchi I, Mochizuki S. The insulin sensitizer pioglitazone improves the deterioration of ischemic preconditioning in Type 2 diabetes mellitus rats. Int Heart J 2007, 48(5):623-635. 10.1536/ihj.48.623, 17998772.
21. Giricz Z, Lalu MM, Csonka C, Bencsik P, Schulz R, Ferdinandy P. Hyperlipidemia attenuates the infarct size-limiting effect of ischemic preconditioning: Role of matrix metalloproteinase-2 inhibition. J Pharmacol Exp Ther 2006, 316(1):154-161.
22. Ungi I, Ungi T, Ruzsa Z, Nagy E, Zimmermann Z, Csont T, Ferdinandy P. Hypercholesterolemia attenuates the anti-ischemic effect of preconditioning during coronary angioplasty. Chest 2005, 128(3):1623-1628. 10.1378/chest.128.3.1623, 16162767.
23. Yadav H N, Singh M, Sharma PL. Involvement of GSK-3β in Attenuation of The Cardioprotective Effect of Ischemic Preconditioning in Diabetic Rat Heart. Mol Cell Biochem 2010, 343(1-2):75-81. 10.1007/s11010-010-0500-z, 20512612.
24. del Valle HF, Lascano EC, Negroni JA. Ischemic preconditioning protection against stunning in conscious diabetic sheep: role of glucose, insulin, sarcolemmal and mitochondrial KATP channels. Cardiovasc Res 2002, 55(3):642-659. 10.1016/S0008-6363(02)00468-6, 12160962.
25. del Valle HF, Lascano EC, Negroni JA, Crottogini AJ. Absence of ischemic preconditioning protection in diabetic sheep hearts: role of sarcolemmal KATP Channel Dysfunction. Mol Cell Biochem 2003, 249(1-2):21-30.
26. Yadav HN, Singh M, Sharma PL. Modulation of the cardioprotective effect of ischemic preconditioning in hyperlipidaemic rat heart. Eur J Pharmacol 2010, 643(1):78-83. 10.1016/j.ejphar.2010.06.015, 20598682.
27. Lisanti MP, Scherer P, Tang Z-L, Sargiacomo M. Caveolae, caveolin and caveolin-rich membrane domains: A signalling hypothesis. Trends Cell Biol 1994, 4(7):231-235. 10.1016/0962-8924(94)90114-7, 14731661.
28. Couet J, Sargiacomo M, Lisanti MP. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J Biol Chem 1997, 272(10):30429-30438.
29. Song KS, Sargiacomo M, Galbiati F, Parenti M, Lisanti MP. Targeting of subunit and c-Src tyrosine kinase to caveolae membranes: clarifying the role of N-myristoylation. Cell Mol Biol 1997, 43(3):293-303.
30. Das M, Cui J, Das DK. Generation of survival signal by differential interaction of p38MAPKα and p38MAPKβ with caveolin-1 and caveolin-3 in the adapted heart. J Mol Cell Cardiol 2007, 42(1):206-213. 10.1016/j.yjmcc.2006.08.118, 2782735, 17069850.
31. Feron O, Balligand JL. Caveolin and the regulation of endothelial nitric oxide synthase in the heart. Cardiovasc Res 2006, 69(4):788-797. 10.1016/j.cardiores.2005.12.014, 16483868.
32. Koneru S, Penumathsa SV, Thirunavukkarasu M, Samuel SM, Zhan L, Han Z, Maulik G, Das DK, Maulik N. Redox regulation of ischemic preconditioning is mediated by the differential activation of caveolins and their association with eNOS and glut-4. Am J Physiol Heart Circ Physiol 2007, 292(5):2060-72.
33. Garlid KD, Costa ADT, Quinlan CL, Pierre SV, Santos PD. Cardioprotective signalling to mitochondria. J Mol Cell Cardiol 2009, 46(6):858-866. 10.1016/j.yjmcc.2008.11.019, 2683183, 19118560.
34. Quinlan CL, Costa ADT, Costa CL, Pierre SV, Dos Santos P, Garlid KD. Conditioning the heart induces formation of signalosomes that interact with mitochondria to open MitoKATP. Am J Physiol 2008, 295(3):H953-61.
35. Garci{dotless}'a-Cardeñ G, Martasek P, Masters BSS, Skidd PM, Coueti J, Lii S, Lisanti MP, Sessa WC. Dissecting the Interaction between Nitric Oxide Synthase (NOS) and Caveolin. Functional significance of the NOS caveolin binding domain in vivo. J Biol Chem 1997, 272(41):25437-25440. 10.1074/jbc.272.41.25437, 9325253.
36. Maniatis NA, Brovkovych V, Allen SE, John TA, Shajahan AN, Tiruppathi C, Vogel SM, Skidgel RA, Malik AB, Minshall RD. Novel mechanism of endothelial nitric oxide synthase activation mediated by caveolae internalization in endothelial cells. Circ Res 2006, 99(8):870-877. 10.1161/01.RES.0000245187.08026.47, 16973909.
37. Bucci M, Roviezzo F, Brancaleone V, Lin MI, Lorenzo AD, Cicala C, Pinto A, Sessa WC, Farneti S, Fiorucci S, Cirino G. Diabetic mouse angiopathy is linked to progressive sympathetic receptor deletion coupled to an enhanced caveolin-1 expression. Arterioscler Thromb Vasc Biol 2004, 24(4):721-6. 10.1161/01.ATV.0000122362.44628.09, 14962949.
38. Penumathsa SV, Thirunavukkarasu M, Zhan L, Maulik G, Menon VP, Bagchi D, Maulik N. Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/AKT/eNOS signaling pathway in diabetic myocardium. J Cell Mol Med 2008, 12(6):2350-2361. 10.1111/j.1582-4934.2008.00251.x, 18266981.
39. Ozansoy G, Akin FB. Effects of gemfibrozil treatment on vascular reactivity of streptozotocin-diabetic rat aorta. J Pharma Pharmacol 2004, 56(2):241-246.
40. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 1969, 6:24-25.
41. Lott J, Turner K. Evaluation of trinder's glucose oxidase method for measuring glucose in serum and urine. Clin Chem 1975, 21(12):1754-1760.
42. Langendorff O. Untersuchungen am uberlebenden Saugethierherzen. Pflugers Arch 1895, 61:291-332.
43. Skrzypiec-Spring M, Grotthus B, Szela{ogonek}g A, Schulz R. Isolated heart perfusion according to Langendorff--Still viable in the new millennium. J Pharmacol Toxicol Methods 2007, 55(2):113-126. 10.1016/j.vascn.2006.05.006, 16844390.
44. Chopra K, Singh M, Kaul N, Ganguly NK. Decrease of myocardial infarct size with desferroxamine. Possible role of oxygen free radicals in it's ameliorative effect. Mol Cell Biochem 1992, 113(1):71-76.
45. Marletta MA, Yoon PS, Iyenger R, Leaf CD, Wishnok JS. Macrophage oxidation of L-arginine to nitrite and nitrate: Nitric oxide is an intermediate. Biochem 1988, 27(24):8706-8711.
46. Szabo C, Thiemermann C, Vane JR. Dihydropyridine modulators of calcium channel inhibit the induction of nitric oxide synthase by endotoxin in cultured J774.2 cells. Biochem Biophys Res Commun 1993, 196(2):825-830. 10.1006/bbrc.1993.2323, 7694580.
47. Szabo C, Wu CC, Mitchell JA, Gross SS, Thiemermann C, Vane JR. Platelet activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ Res 1993, 73(6):991-999.
48. Parikh V, Singh M. Possible role of cardiac mast cell degranulation and preservation of nitric oxide release in isolated rat heart subjected to ischemic preconditioning. Mol Cell Biochem 1999, 199:1-6. 10.1023/A:1006930011622, 10544945.
49. Grover GJ, Dzwonczyk S, Sleph PG, Sergent CVR. The ATP sensitive potassium channel blocker. Glibenclamide (Glyburide) does not abolish preconditioning in isolated ischaemic rat heart. J Phamacol Exp Ther 1993, 265(2):559-65.
50. Fralix TA, Steenbergen C, London RE, Murphy E. Glibenclamide does not abolish the protective effect of preconditioning on stunning in the isolated perfused rat heart. Cardiovasc Res 1997, 27(4):630-7.
51. Kaur H, Parikh V, Sharma A, Singh M. Effect of amiloride a Na+/H+ exchange inhibitor on cardioprotective effect of ischaemic preconditioning: possible involvement of resident cardiac mast cells. Pharmacol Res 1997, 36(2):95-102. 10.1006/phrs.1997.0174, 9344636.
52. Kersten JR, Toller WG, Gross ER, Pagel PS, Warltier DC. Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol 2000, 278(4):H1218-H1224.
53. Wynne A, Hausenloy DJ, Mocanu MM, Yellon DM. Glimepiride reduces the threshold for ischemic preconditioning in the diabetic heart. J Mol Cell Cardiol 2007, 42:S171-S189.
54. Gross ER, Hsu AK, Gross GJ. Diabetes Abolishes Morphine-Induced Cardioprotection via Multiple Pathways Upstream of Glycogen Synthas Kinase-3β. Diabetes 2007, 56(1):127-136. 10.2337/db06-0907, 17192474.
55. Webb A, Bond R, McLean P, Uppal R, Benjamin N, Ahluwalia A. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. PNAS 2004, 101:13683-13688. 10.1073/pnas.0402927101, 518813, 15347817.
56. Baker JE, Su J, Fu X, Hsu A, Gross GJ, Tweddell JS, Hogg N. Nitrite confers protection against myocardial infarction: Role of xanthine oxidoreductase, NADPH oxidase and KATP channels. J Mol Cell Cardiol 2007, 43(4):437-444. 10.1016/j.yjmcc.2007.07.057, 2735077, 17765919.
57. Taliyan R, Singh M, Sharma PL, Yadav HN, Sidhu KS. Possible involvement of α 1 adrenergic receptor and KATP channels in cardioprotective effect of remote aortic preconditioning in isolated rat heart. J C D R 2010, 1(3):145-151.
58. Baines CP, Cohen MV, Downey JM. Signal Transduction in Ischemic Preconditioning:The Role of Kinases and Mitochondrial KATP Channels:. J Cardiovasc Electrophysiol 1999, 10(5):741-754. 10.1111/j.1540-8167.1999.tb00251.x, 10355930.
59. Murphy E. Primary and secondary signalling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection. Circ Res 2004, 94(1):7-16. 10.1161/01.RES.0000108082.76667.F4, 14715531.
60. Hide EJ, Thiemermann C. Limitation of myocardial infarct size in the rabbit by ischaemic preconditioning is abolished by sodium 5-hydroxydecanoate. Cardiovasc Res 1996, 31(6):941-946.
61. Yang M-K, Lee S-H, Seo H-W, Yi K-W, Yoo S-E, Lee B-H, Chung H-J, Won H-S, Lee C-S, Kwon S-H, et al. KR-31761, a Novel K+ATP Channel Opener, Exerts Cardioprotective Effects by Opening Both Mitochondrial K+ATP and Sarcolemmal K+ATP Channels in Rat Models of Ischemia/Reperfusion-Induced Heart Injury. J Pharmacol Sci 2009, 109(2):222-232. 10.1254/jphs.08132FP, 19234365.
62. Koneru S, Penumathsa SV, Thirunavukkarasu M, Samuel SM, Zhan L, Han Z, Maulik G, Das DK, Maulik N. Redox regulation of ischemic preconditioning is mediated by the differential activation of caveolins and their association with eNOS and GLUT-4. Am J Physiol Heart Circ Physiol 2007, 292(5):H2060-H2072. 10.1152/ajpheart.01169.2006, 17277024.
63. Feron O, Belhhassen L, Kobzik L, Smith TW, Kelly RA, Michel T. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem 1996, 271(37):22810-22814. 10.1074/jbc.271.37.22810, 8798458.
64. Sobey GC, Weiler MJ, Boujaoude M, Woodman LO. Effect of short-term phytoestrogen treatment in male rats on nitric oxide- mediated responses of carotid and cerebral arteries: comparison with 17-β estradiol. J Pharmacol Exp Ther 2004, 310(1):135-140. 10.1124/jpet.103.063255, 15054117.
65. Woodman OL, Missen MA, Boujaoude M. Daidzein and 17 beta-estradiol enhance nitric oxide synthase activity associated with an increase in calmodulin and a decrease in caveolin-1. J Cardiovasc Pharmacol 2004, 44(2):155-163. 10.1097/00005344-200408000-00003, 15243295.
66. Tsutsumi YM, Kawaraguchi Y, Horikawa YT, Niesman IR, Kidd MW, Chin-Lee B, Head BP, Patel PM, Roth DM, Patel HH. Role of caveolin-3 and glucose transporter-4 in isofurane induced delayed cardioprotection. Anesthesiology 2010, 112(5):1136-1145. 10.1097/ALN.0b013e3181d3d624, 2860616, 20418694.
67. Osada M, Takeda S, Sato T, Komori S, Tamura K. The protective effect of preconditioning on reperfusion induced arrhythmia is lost by treatment with superoxide dismutase. Jpn Circ 1994, 58:259-263.
68. Tanaka M, Fujiwara H, Yamasaki K, Sasayama S. Superoxide dis-mutase and N-2 mercaptopropionyl glycine attenuate infarct size limitation effect of ischemic preconditioning in the rabbit. Cardiovasc Res 1994, 28:980-986. 10.1093/cvr/28.7.980, 7954610.
69. Roth DM, Patel HH. Role of caveolae in cardiac Protection. Pediatr Cardiol 2011, 32(3):329-333. 10.1007/s00246-010-9881-8, 3051068, 21210089.